Agerafenib

SKU: orb1306565

Description

Agerafenib (CEP32496) is a potent and selective BRAF kinase inhibitor. It is used in biochemical and cellular research to study oncogenic BRAF signaling and has demonstrated activity in preclinical in vitro and in vivo models of BRAF-mutant cancers.

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 1188910-76-0
• MW: 517.46
• Purity: 99.23% (May vary between batches)
• Formula: C₂₄H₂₂F₃N₅O₅
• SMILES: COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC
• Target: Bcr-Abl,Src,c-Kit,Raf,c-RET,PDGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.87 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:45 mg/mL (86.96 mM)

Bioactivity

• Target IC50:
  B-Raf (V600E):14 nM (Kd)|EGFR:22 nM (Kd)|RET:2 nM(Kd)|VEGFR2:8 nM (Kd)|c-Met:513 nM (Kd)|MEK1:7100 nM (Kd)|B-Raf:36 nM (Kd)|Lck:2 nM(Kd)|Abl-1:3 nM(Kd)|CSF1R:9 nM (Kd)|MEK2:8300 nM (Kd)|Raf:39 nM (Kd)|c-Kit:2 nM(Kd)|PDGFRβ:2 nM(Kd)|JAK2:4700 nM (Kd)|EPHA2:14 nM (Kd)
• In Vivo:
  CEP-32496 inhibited MAPK/MEK phosphorylation in human melanoma and colorectal cancer cell lines with IC50 of 78 nM and 60 nM.CEP-32496 inhibited the proliferation of A375 cells (BRAFV600E) with an EC50 of 78 nM.CEP-32496 acted on tumor cell lines, and inhibited the proliferation of A375, SK-MEL-28, CEP-32496 acts on tumor cell lines and is more sensitive to the cytotoxicity of mutant BRAF-expressing A375, SK, MEL-28, Colo-205, Colo-679 and HT-144 cells than wild-type BRAF-expressing HCT116, Hs578T, LNCaP, DU145 and PC-3 cells.
• In Vitro:
  In the Colo-205 xenograft mouse model CEP-32496 (30 mg/kg, oral, BID) showed a 40% incidence of tumor arrest and partial tumor regression (PR), while the 100 mg/kg dose group showed an 80% incidence of tumor arrest and PR. Twice-daily oral treatment of tumor lysates with 30 mg/kg CEP-32496 inhibited 50% and 75% of normalized pMEK at 2 and 6 hours after dosing, respectively, whereas treatment of a mouse model bearing Colo-205 transplanted tumors with 55 mg/kg CEP-32496 for 2 to 10 hours inhibited 57% to 75% of pMEK. 32496 was orally bioavailable in a variety of preclinical species (> 95% in rats, dogs and monkeys).100 mg/kg CEP-32496 treatment resulted in inhibition of pMEK and pERK and sustained tumor arrest and regression in BRAF (V600E) colon cancer xenografts in nude mice.CEP-32496 showed good stability in mouse, dog, monkey, and human hepatic microsomal formulations. CEP-32496 exhibited good stability with intrinsic clearance values of <23 (μL/min)/ mg and t1/2> 60 min measured in all assays.
• Cell Research:
  Cells are seeded at 104 cells per well in DMEM with 10% fetal calf serum and allowed to attach. The cells are washed with PBS and switched to DMEM with 0.5% of serum and incubated overnight. CEP-32496 is then added at various concentrations with a final DMSO concentration of 0.5% and incubated for 72 h. At the end of incubation, a Cell Titer Blue is added per instructions, and incubation is continued for 3 hours. Remaining viable cells are quantified by measuring the strength of the fluorescence signal using SoftMax Pro (excitation at 560 nm and emission at 590 nm). IC50 values are derived using a 9-point curve fitted with Igor Pro and are presented as mean values from experiments performed in duplicate. Variability between individual values is less than 2-fold.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cRET, CEP32496, CEP-32496, CEP 32496, c-Kit, cKit, Abl1, Agerafenib, BcrAbl, Lck, Inhibitor, inhibit, PDGFRβ, RXDX 105, RXDX105, RXDX-105, RET, Raf, Raf kinases

Compound Identifiers

PubChem CID

56846693